Value of FGFR alterations on treatment outcomes in bladder cancer: a multicenter collaboration project

Value of FGFR alterations on treatment outcomes in bladder cancer: a multicenter collaboration project - FOsMIC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00016925

Enrollment

120

Registered

2019-04-18

Start date

2018-04-09

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67 C64 C56 C66 C68

Interventions

Group 1: Patients with advanced urothelial cancer (bladder or upper urinary tract) who have received anti-PD-(L)1 therapy with at least two months of follow-up. FGFR alterations will be analyzed in tu

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult patients =18 years old. Patients with histologically confirmed advanced bladder cancer. Patients who have received anti-PD-(L)1 therapy

Exclusion criteria

Exclusion criteria: < 18 years old.

Design outcomes

Primary

Measure	Time frame
Tumor recurrance and progression in patients with FGFR-Alterations in advanced urothelial carcinoma after anti-PD-1 or anti-PD-L1 therapies.	—

Secondary

Measure	Time frame
Association of molecular subtype with clinical activity of anti-PD-1 or anti-PD-L1 therapies.	—

Countries

Germany

Contacts

Public ContactPhilipp Erben

Klinik für Urologie Medizinische Fakultät Mannheim der Universität Heidelberg

philipp.erben@medma.uni-heidelberg.de+49-621-383-1610

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026